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Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and progressive lung disease1 and
represents an important public health challenge2. Pharmacological treatment of COPD continues to be a
challenging problem for clinicians in the US, especially in rural areas3. In spite of various treatment
combinations, high 30-day readmissions for this disease continue to be a problem for hospitals facing
penalties under Medicare Hospital Readmissions Reduction Program (HRRP) 4. The most common
pharmacological treatment combinations, fluticasone/salmeterol (Advair) and budesonide/formoterol
(Symbicort), appear to be effective treatment options. However, an independent validation of the
effectiveness of these treatments, and their combination with tiotropium (Spiriva), on controlling early
hospital readmission is needed. Our study on the readmission rates between these combination and triple
combination treatments will fill this gap.
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In this study, we conducted a phase IV (after market release) retrospective drug trial of combination
treatments: fluticasone/salmeterol and budesonide/formoterol; triple combination treatments:
budesonide/formoterol/tiotropium and fluticasone/salmeterol/tiotropium. Patient data came from a
clinical dataset donated to Oklahoma State University by the Cerner Corporation. Data was utilized to
compare 30-day readmission rates among COPD patients prescribed these common COPD treatment
options. Using propensity score matching and chi-square analysis on patient demographics and hospital-
associated variables, we tested for differences in readmission rates among patient populations in this
matched cohort study. Relative risks (RR) and confidence interval (CI) estimates were also obtained and
compared. Covariates used for these analyses were drug type, ethnicity, marital status, payer type,
gender, and hospital location.
Descriptive Statistics
Population Drug Treatment Total No. of 
Patients
No. of Patients 
Readmitted
Readmission % P value
Drug Type
Fluticasone/salmeterol 8502 1323 7.78%
0.087
Budesonide/formoterol 8502 1243 7.31%
African American
Fluticasone/salmeterol 1273 202 8.22%
0.133
Budesonide/formoterol 1185 215 8.75%
Asian
Fluticasone/salmeterol 51 4 3.88%
0.056
Budesonide/formoterol 52 11 10.68%
Caucasian
Fluticasone/salmeterol 6693 1050 7.74%
0.004
Budesonide/formoterol 6877 959 7.07%
Hispanic
Fluticasone/salmeterol 62 11 10.19%
0.81
Budesonide/formoterol 46 9 8.33%
Native American
Fluticasone/salmeterol 53 5 5.32%
0.958
Budesonide/formoterol 41 4 4.26%
Biracial/Other
Fluticasone/salmeterol 171 27 8.36%
0.436
Budesonide/formoterol 152 29 8.98%
Divorced
Fluticasone/salmeterol 1689 264 8.34%
0.783
Budesonide/formoterol 1476 236 7.46%
Married
Fluticasone/salmeterol 3011 437 8.88%
0.578
Budesonide/formoterol 3146 441 7.51%
Single
Fluticasone/salmeterol 1923 317 8.35%
0.145
Budesonide/formoterol 1874 277 7.30%
Widowed
Fluticasone/salmeterol 1598 272 8.17%
0.088
Budesonide/formoterol 1730 257 7.72%
Self-Pay
Fluticasone/salmeterol 248 36 8.08%
0.008
Budesonide/formoterol 197 13 2.92%
Medicare/ Medicaid
Fluticasone/salmeterol 4839 842 8.68%
0.019
Budesonide/formoterol 4857 759 7.83%
Private Insurance
Fluticasone/salmeterol 522 54 5.90%
0.690
Budesonide/formoterol 394 44 4.80%
Female
Fluticasone/salmeterol 4787 750 7.94%
0.072
Budesonide/formoterol 4663 669 7.08%
Male
Fluticasone/salmeterol 3715 573 7.59%
0.568
Budesonide/formoterol 3839 574 7.60%
Rural Location
Fluticasone/salmeterol 1313 218 6.32%
0.915
Budesonide/formoterol 2138 352 10.20%
Urban Location
Fluticasone/salmeterol 7189 1105 8.15%
0.025
Budesonide/formoterol 6364 891 6.57%
Population Drug Treatment Total No. of 
Patients
No. of Patients 
Readmitted
Readmission % P value
Drug Type
Fluticasone/Salmeterol/Tiotropium 5553 1008 9.08%
0.045
Budesonide/formoterol/Tiotropium 5553 928 8.36%
African American
Fluticasone/salmeterol/Tiotropium 831 145 9.21%
0.030
Budesonide/formoterol/Tiotropium 743 162 10.29%
Asian
Fluticasone/salmeterol/Tiotropium 35 9 16.98%
0.560
Budesonide/formoterol/Tiotropium 18 6 11.32%
Caucasian
Fluticasone/salmeterol/Tiotropium 4351 804 9.09%
0.0008
Budesonide/formoterol/Tiotropium 4493 710 8.03%
Hispanic
Fluticasone/salmeterol/Tiotropium 44 8 9.41%%
0.444
Budesonide/formoterol/Tiotropium 41 5 5.88%%
Native American
Fluticasone/salmeterol/Tiotropium 27 3 6.00%
0.834
Budesonide/formoterol/Tiotropium 23 3 6.00%
Biracial/Other
Fluticasone/salmeterol/Tiotropium 127 22 9.57% 0.341
Budesonide/formoterol/Tiotropium 103 23 10.00%
Divorced
Fluticasone/salmeterol/Tiotropium 922 185 9.50%
0.088
Budesonide/formoterol/Tiotropium 1026 175 8.98%
Married
Fluticasone/salmeterol/Tiotropium 2057 362 8.88%
0.035
Budesonide/formoterol/Tiotropium 2020 306 7.51%
Single
Fluticasone/salmeterol/Tiotropium 893 139 6.72%
0.125
Budesonide/formoterol/Tiotropium 1175 213 10.30%
Widowed
Fluticasone/salmeterol/Tiotropium 1146 225 9.82%
0.489
Budesonide/formoterol/Tiotropium 1146 212 9.25%
Self-Pay
Fluticasone/salmeterol/Tiotropium 130 14 5.98%
0.589
Budesonide/formoterol/Tiotropium 104 9 3.85%
Medicare/ Medicaid
Fluticasone/salmeterol/Tiotropium 3065 632 10.00%
0.043
Budesonide/formoterol/Tiotropium 3258 606 9.58%
Private Insurance
Fluticasone/salmeterol/Tiotropium 378 60 9.45%
0.434
Budesonide/formoterol/Tiotropium 257 35 5.51%
Female
Fluticasone/salmeterol/Tiotropium 2883 517 8.93%
0.181
Budesonide/formoterol/Tiotropium 2909 483 8.34%
Male
Fluticasone/salmeterol/Tiotropium 2670 291 9.24%
0.136
Budesonide/formoterol/Tiotropium 2644 445 8.37%
Rural Location
Fluticasone/salmeterol/Tiotropium 677 124 6.16%
0.711
Budesonide/formoterol/Tiotropium 1337 254 12.61%
Urban Location
Fluticasone/salmeterol/Tiotropium 4876 884 9.72%
0.007
Budesonide/formoterol/Tiotropium 4216 674 7.41%
Tables 1 and 2 above show the total number of patients, the number of patients readmitted, and the 30-day readmission rates for each
category.
Table 1: Chi-square analyses on readmission rates for combination therapies indicate that there is a significant difference in the 30-
day readmission rates for Caucasians, patients who self-pay or utilize Medicare/Medicaid, and patients in urban locations.
Table 2: Chi-square analyses on readmission rates for triple therapies indicate that there is a significant difference in the 30-day
readmission rates between drug types, as well as patients who are African Americans, Caucasians, married, utilize
Medicare/Medicaid, and patients in urban locations.
The p-values are obtained from the association test indicating that if p < 0.05 then there is a significant association between the
categories and 30-day readmission (indicated in red).
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Drug Comparison by Payer Type
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Drug Comparison by Hospital Location
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30-Day Readmission Rate by Drug
30-day readmission rates for different ethnicities, payers and hospital locations for combination and triple combination drugs are 
shown in Figure 1 - 3. Figure 4 represents the difference in 30-day readmission rates for combination  and triple combination drugs. 
Advair = fluticasone/salmeterol (blue/blue stiped bars); Symbicort = budesonide/formoterol (orange/orange striped bars); Spiriva = 
Tiotropium. P=<0.05 was considered significant (*).
Chi-square analysis showed that number of 30-day readmissions between combination drugs were
significantly different in Caucasians [7.74 vs 7.07%; RR 1.13; CI 1.04-1.22; p<0.05], patients who self-
pay [8.09 vs 2.92%; RR 2.2; CI 1.2-4.03; p<0.05], utilize Medicare/Medicaid [8.68 vs 7.83%; RR
1.114; CI 1.018-1.22; p<0.05] and patients in urban hospital locations [8.15 vs 6.57%; RR 1.1; CI
1.012-1.19; p<0.05]. Triple combination therapies had significantly different number of 30-day
readmissions in African Americans [9.21 vs 10.29%; RR 1.25; CI 1.02-1.53; p<0.05], Caucasians [9.09
vs 8.03%; RR 1.17; CI 1.07-1.28; p<0.001], patients who utilize Medicare/Medicaid [10.0 vs 9.58%;
RR 1.11; CI 1.0003-1.23; p<0.05] and patients in urban hospital locations [9.72 vs 7.41%; RR 1.13; CI
1.04-1.24; p<0.05]. No significant differences in number of 30-day readmissions between combination
drugs (Advair vs Symbicort) were found. In contrast, separate chi-square analysis revealed significant
differences in number of 30-day readmissions between triple combination therapies (Advair/Spiriva vs
Symbicort/Spiriva) [9.08 vs 8.36%; RR 1.09; CI 1.002-1.18; p < 0.05].
Analysis of 30-day readmission rates between triple therapies showed that
Fluticasone/salmeterol/tiotropium readmission rates were significantly higher than
Budesonide/formoterol/tiotropium readmission rates. However, differences in rates were non-significant
for combination therapies. When other covariates were considered further differences were highlighted,
with budesonide/formoterol and budesonide/formoterol/tiotropium having lower readmission rates
except in African Americans. Identifying drug therapies that have lower 30-day readmission among
COPD patients could influence clinical decisions as providers make choices regarding patient care such
as hospital length of stay and discharge options. However, due to the observational nature we cannot
conclude with certainty that medication was the only factor responsible for any differences observed in
this study. Further studies are needed to confirm and could provide information to guide further
research for therapeutics and tools to better patient management post discharge.
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